Rovida Advisors’s Calumet Specialty Products CLMT Stock Holding History

Rovida Advisors’s Portfolio CLMT Stock Details CLMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-859,520	Closed	-$3.4M	–	19
2016 Q4	$3.4M	Sell	859,520 -235,520	-22%	-$961K	0.75%	15
2016 Q3	$4.95M	Buy	1,095,040 +220,040	+25%	+$1.13M	2.46%	8
2016 Q2	$4.27M	Buy	+875,000	New	+$4.96M	2.8%	9

Other funds holding CLMT

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SPCM

Sound Point Capital Management New York $28.3M AUM 13.25% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AAA

Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Rovida Advisors's CLMT Position: Q1 2017 in Review

Rovida Advisors sold out of Calumet Specialty Products (CLMT) in Q1 2017, closing a stake of 859,520 shares — an estimated $3.4M sold.

Rovida Advisors first reported a position in CLMT in Q2 2016 and held it in 3 quarters. The position peaked at $4.95M in Q3 2016. 68 funds tracked by Wall St. Rank hold CLMT as of Q1 2017.

Rovida Advisors reported no remaining Calumet Specialty Products position as of Q1 2017 after selling out during the quarter.
Rovida Advisors sold 859,520 Calumet Specialty Products shares in Q1 2017, an estimated $3.4M.
Rovida Advisors first reported a position in Calumet Specialty Products in Q2 2016 and held it in 3 quarters.
Rovida Advisors's Calumet Specialty Products position peaked at $4.95M in Q3 2016.
68 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q1 2017.

Based on Rovida Advisors's 13F filing for Q1 2017, filed 3 May 2017.